Aceso Life Science Announces Update on Joint Venture Formation with Jiangsu Lettall

Reuters
05-13
Aceso Life Science Announces Update on Joint Venture Formation with Jiangsu Lettall

Aceso Life Science Group Ltd. announced an update regarding the formation of a joint venture with Jiangsu Lettall. Initially disclosed on 30 March 2025, the joint venture agreement entails HTICI, a subsidiary of Aceso, and Jiangsu Lettall owning 75% and 25% of the JV Company, respectively. Recently, HTICI completed a share placement, leading to a dilution of Aceso's holding in HTICI. Consequently, HTICI's results and financial position will no longer be consolidated into Aceso's financial statements but will be accounted for separately as an associate. This update affects the company's reporting obligations regarding the joint venture agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aceso Life Science Group Ltd. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10